Aenduo, Telemedicine for Chronic Respiratory Diseases, Launches Capital Raise on CrowdFundMe

Innovative SME Aenduo produces and markets the AdvantCare cloud platform for remotely treating patients with respiratory diseases.

To support commercial and technological growth, Aenduo has launched an equity crowdfunding campaign on CrowdFundMe, which will end in mid-October and which has so far raised around 420,000 euros.

There is still room to aim for the maximum target of 1.3 million, against a pre-money valuation of 16.5.

Aenduo capital increase through equity crowdfunding follows an initial collection of 500,000 euros, in 2021, by Angel Investor and was a choice encouraged by the company’s employees, eager to take an increasingly greater part in the company’s history and future by becoming its partners.

AdvantCare: a telemedicine solution already adopted by 160 thousand patients according to Aenduo

The AdvantCare platform, certified as Class IIA medical software, allows tele-monitoring of biomedical parameters and therapies, tele-surveillance, tele-diagnostics, tele-visits and empowerment, with a significant reduction in time and costs for healthcare professionals and patients.

The digital health suite, in two years, has gone from 5,000 to 160,000 connected patients in 8 European countries, integrates more than 100 devices and is the leader in Italy with a market share in the respiratory sector of over 60%.

Aenduo closed 2023 with a turnover of 1.5 million euros and in the first half of 2024 revenues rose by 102% compared to the same period of the previous year, reaching 782,636 euros.

The company, which has invested 1.5 million euros in research and development, filing two industrial invention patents and three trademarks at European level, aims to reach one million patients in 2027 and revenues exceeding 11 million euros.

Aenduo also boasts collaborations with numerous Italian and international research institutions, including the Sapienza, Cattolica, Tor Vergata, Sassari Universities, HESAV – Haute Ecole de Santé du Canton de Vaud in Lausanne and the University Hospital of Geneva.

Present and future developments thanks to a team of biomedical and computer engineers
The team, led by Marcello Pediconi and Michelangelo Smeriglio , is made up of about twenty professionals including biomedical engineers and information technology experts.

“ We have decided to specialize in the respiratory disease sector and we are gaining an important position in Italy and Europe; the number of patients we already have active in 2024 corresponds to more than half of Italy’s objective for the end of 2025,” said Michelangelo Smeriglio, COO.

The AdvantCare suite becomes even more cutting-edge thanks to a new service based on artificial intelligence that allows you to perform a face scan from your smartphone and suggest the most suitable facial mask for each person’s physiognomy, thus promoting better therapy performance.

The service will be launched in the next few days during the ERS, the most important scientific congress in Europe in the respiratory field, during which “more than 150 pulmonologists, physiotherapists and professionals from all over Europe have requested a demo”, concluded Smeriglio.

The funds raised on CrowdFundMe, aimed at accelerating the company’s international growth with the goal of reaching 1 million patients by 2027, will be used to strengthen research and development (30%), sales and operations (55%) and marketing (15%) activities.

__

(Featured image by Tumisu via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Crowdfunding buzz. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us